Synendos Therapeutics

Synendos Therapeutics is a Swiss, private biotech advancing a novel class of drugs called Selective Endocannabinoid Reuptake Inhibitors (SERIs) to treat major neuropsychiatric disorders. The company's lead asset, SYT-510, has completed Phase 1 trials with positive results and is poised to enter Phase 2 development for conditions such as GAD and PTSD. Founded on pioneering academic research, Synendos is backed by a syndicate of European life science investors and aims to provide a new, physiology-based treatment modality for the vast, underserved mental health market.

Platform for developing Selective Endocannabinoid Reuptake Inhibitors (SERIs), a novel class of small molecules designed to modulate the endocannabinoid system by inhibiting the reuptake of endogenous cannabinoids, aiming to restore physiological balance without overstimulation.

Competition includes established SSRIs/SNRIs and emerging therapies targeting other mechanisms for anxiety and PTSD. While no other SERI programs are known, the field of ECS modulation is active with companies exploring CB1/CB2 receptor agonists, antagonists, and FAAH inhibitors, though Synendos's reuptake inhibition approach is distinct.